% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • jsblvbjb jsblvbjb Feb 19, 2014 9:07 PM Flag

    Arikace is being used to treat Pneumonia... Surprise!!!

    Well, sort of. Aerosolized Amikacin in combo with another antibiotic and delivered by the eFlow Pari Nebulizer is being used to tread gram-negative pneumonia patients in clinical trial right now across the nation. Is there any doubt that Arikace will be prescribed for pneumonia once approved for NTM and/or CF? I don't have any!

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • This is interesting:

      PHILADELPHIA (CBS) – The data is scary: Nearly half of water faucets sampled across the United States tested positive for the bacteria that causes Legionnaires’ disease.

      While the study was small — researchers only sampled 67 public and private water sources such as kitchen sinks and drinking fountains – it’s the first one to chart the presence of the potentially deadly bacteria in water taps.

      According to the EPA, the organization that conducted the research, 32 taps contained the bacteria, and 11 of those contained it in multiple samples.

      Legionnaires’ disease is a severe form of pneumonia that causes chills, fever, headache, a cough and more. It can be deadly.

      The study was published on Feb. 18 in the journal Environmental Science & Technology

      Sentiment: Strong Buy

    • Worth noting that an Advanced Search of ClinicalTrialsDOTgov - specifying the Condition as pneumonia and the Intervention as amikacin - reveals thirteen studies, of which at least the first seven relate to pulmonary delivery.

      Equally important is the following extract from the Kalorama Information Drug Delivery Market Reports, Drug Delivery Markets, Vol III: Pulmonary Delivery Systems -

      [ The lungs are considered by many to be the best alternative for drugs needing to bypass the gastrointestinal tract. With advancing technology, the practice of utilizing the huge surface area of the lungs to delivery drugs into the blood circulation has been slowly transforming into reality.

      The pulmonary drug delivery market reached $25.5 billion in 2006 and is expected to experience high steady growth in the next five years. ]

      The key question here is -

      Why should an inhaled drug targeted at a pulmonary condition behave any differently to an inhaled drug targeted at a condition elsewhere in the body?

    • This could be a strategic purchase W Lewis mentioned for the future. This drug is on fast track and could be available for market next year.

14.04-0.03(-0.21%)Oct 21 4:00 PMEDT